Johan W.M. Heemskerk

Prof. Dr. Johan W.M. Heemskerk

Synapse Research Institute, Kon. Emmaplein 7, 6214 AC Maastricht, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
HVHenri Versteeg
Henri Versteeg
Johan W.M. HeemskerkJohan W.M. Heemskerk
Johan W.M. Heemskerk
MLMarcel Levi
Marcel Levi
PRPieter H. Reitsma
Pieter H. Reitsma
Hemostasis encompasses the tightly regulated processes of blood clotting, platelet activation, and vascular repair. After wounding, the hemostatic system engages a plethora of vascular and extravascular receptors that act in concert with blood components to seal off the damage inflicted to the vasculature and the surrounding tissue. The first important component that contributes to hemostasis is the coagulation system, while the second important component starts with platelet activation, which not only contributes to the hemostatic plug, but also accelerates the coagulation system. Eventually, coagulation and platelet activation are switched off by blood-borne inhibitors and proteolytic feedback loops. This review summarizes new concepts of activation of proteases that regulate coagulation and anticoagulation, to give rise to transient thrombin generation and fibrin clot formation. It further speculates on the (patho)physiological roles of intra- and extravascular receptors that operate in response to these proteases. Furthermore, this review provides a new framework for understanding how signaling and adhesive interactions between endothelial cells, leukocytes, and platelets can regulate thrombus formation and modulate the coagulation process. Now that the key molecular players of coagulation and platelet activation have become clear, and their complex interactions with the vessel wall have been mapped out, we can also better speculate on the causes of thrombosis-related angiopathies.

14 November 2018 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
PMPoala van der Meijden
Poala van der Meijden
Johan W.M. HeemskerkJohan W.M. Heemskerk
Johan W.M. Heemskerk

1 May 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
BNBernhard Nieswandt
Bernhard Nieswandt
Cord Brakebusch (Ref.: 30372500-5001005001)Cord Brakebusch (Ref.: 30372500-5001005001)
Cord Brakebusch (Ref.: 30372500-5001005001)
WBWolfgang Bergmeier
Wolfgang Bergmeier
VSValerie Schulte
Valerie Schulte
DBDaniel Bouvard
Daniel Bouvard
RFReinhard Fässler
Reinhard Fässler
Platelet adhesion on and activation by components of the extracellular matrix are crucial to arrest post‐traumatic bleeding, but can also harm tissue by occluding diseased vessels. Integrin α2β1 is thought to be essential for platelet adhesion to subendothelial collagens, facilitating subsequent interactions with the activating platelet collagen receptor, glycoprotein VI (GPVI). Here we show that Cre/loxP‐mediated loss of β1 integrin on platelets has no significant effect on the bleeding time in mice. Aggregation of β1‐null platelets to native fibrillar collagen is delayed, but not reduced, whereas aggregation to enzymatically digested soluble collagen is abolished. Furthermore, β1‐null platelets adhere to fibrillar, but not soluble collagen under static as well as low (150 s−1) and high (1000 s−1) shear flow conditions, probably through binding of αIIbβ3 to von Willebrand factor. On the other hand, we show that platelets lacking GPVI can not activate integrins and consequently fail to adhere to and aggregate on fibrillar as well as soluble collagen. These data show that GPVI plays the central role in platelet‐collagen interactions by activating different adhesive receptors, including α2β1 integrin, which strengthens adhesion without being essential.

1 January 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KCKeren J. Carss
Keren J. Carss
GAGavin Arno
Gavin Arno
MEMarie Erwood
Marie Erwood
JSJonathan Stephens
Jonathan Stephens
ASAlba Sanchis-Juan
Alba Sanchis-Juan
PYPing Yu
Ping Yu

1 January 2002 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
EBEdouard M. Bevers
Edouard M. Bevers
TLTheo Lindhout
Theo Lindhout
Johan W.M. HeemskerkJohan W.M. Heemskerk
Johan W.M. Heemskerk
Platelet activation and blood coagulation are complementary, mutually dependent processes in haemostasis and thrombosis. Platelets interact with several coagulation factors, while the coagulation product thrombin is a potent platelet-activating agonist. Activated platelets come in a procoagulant state after a prolonged elevation in cytosolic [Ca2+]i. Such platelets, e. g. when adhering to collagen via glycoprotein VI, expose phosphatidylserine (PS) at their outer surface and produce (PS-exposing) membrane blebs and microvesicles. Inhibition of aminophospholipid translocase and activation of phospholipid scramblase mediate the exposure of PS, whereas calpain-mediated protein cleavage leads to membrane blebbing and vesiculation. Surface-exposed PS strongly propagates the coagulation process by facilitating the assembly and activation of tenase and prothrombinase complexes. Factor IXa and platelet-bound factor Va support these activities. In addition, platelets can support the initiation phase of coagulation by providing binding sites for prothrombin and factor XI. They thereby take over the initiating role of tissue factor and factor VIIa in coagulation activation.

1 January 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
Johan W.M. HeemskerkJohan W.M. Heemskerk
Johan W.M. Heemskerk
NMN. J. A. Mattheij
N. J. A. Mattheij
Judith CosemansJudith Cosemans
Judith Cosemans